Introduction
============

Nitric oxide synthase (NOS) inhibition is currently investigated as a treatment of arterial hypotension associated with septic shock, but controversial data are available with respect to hepatic O~2~ balance. Therefore we studied the effect of NOS inhibition with L-NMMA on liver O~2~ transport as well as energy balance, in comparison to a standard treatment with noradrenaline (NOR) in a hyperdynamic endotoxin (ETX) shock model.

Methods
=======

Thirty anesthetized pigs were randomly assigned to 3 groups 12 h after induction of endotoxic shock with continuous LPS infusion: ETX group: no drug therapy (*n* = 8); NOR group (*n* = 11) and L-NMMA group (*n* = 11): vasopressor therapy with NOR and L-NMMA was titrated to maintain MAP at preshock levels. Hepatic blood flow (Transonic^®^ Doppler ultrasound), O~2~ kinetics as well as mean and frequency distribution of intracapillary HbO~2~ saturation (remission spectrophotometry, EMPHO) were measured.

Results
=======

Data are median and interquartile range. \**P* \< 0.05 vs preshock (RM ANOVA on ranks). \*\**P* \< 0.05 between groups (ANOVA).

Conclusions
===========

Although, in contrast to NOR, L-NMMA did notfurther increase macrocirculatory liver O~2~ availability, there was no difference between the two treatments with regard to microcircula-tory O~2~ supply and O~2~ uptake. Hence, neither of the two treatments improved liver energy balance.

                                  Preshock              12 h                 18 h                  24 h
  ------------------ ------------ --------------------- -------------------- --------------------- --------------------
  Liver DO~2~        ETX          2.3 \[1.9;2.8\]       2.2 \[1.7;2.7\]      2.7 \[2.0;3.0\]       2.0 \[1.4;2.6\]
  ml/min/kg          NOR^\*^      2.3 \[1.8;2.8\]       2.0 \[1.5;2.4\]      3.1 \[2.8;3.6^\*\*^   2.6 \[1.9;4.1\]
                     L-NMMA       2.5 \[2.2; 2.9\]      2.5 \[2.1 ;2.61      2.3 \[1.7;2.8\]       2.0 \[1.1;2.6\]
  Hepatic            ETX          54 ± 5                51 ± 7               51 ± 7                47 ± 10
  intracap. HbO~2~   NOR          59 ± 6                54 ± 8               61 ± 7                58 ± 12
  Mean ± SD          L-NMMA       59 ± 8                56 ± 10              55 ± 10               58 ± 7
  Liver VO~2~        ETX          0.7 \[0.5;1.1\]       0.6 \[0.4;0.8\]      0.6 \[0.4;0.8\]       0.6 \[0.3;0.7\]
  ml/min/kg          NOR          0.7 \[0.5;1.1\]       0.6 \[0.4;0.8\]      0.6 \[0.4;0.8\]       0.6 \[0.3;0.7\]
                     L-NMMA       0.8 \[0.5;0.8\]       0.8 \[0.5;1.0\]      0.6 \[0.4;0.8\]       0.5 \[0.3;0.8\]
  Hepatic            ETX^\*^      7.48 \[17.46;7.50\]   7.38 \[7.34;7.42\]   7.36 \[7.34;7.381     7.30 \[7.25;7.34\]
  venous pH          NOR^\*^      7.49 \[7.46;7.51\]    7.33 \[7.25;7.34\]   7.32 \[7.2817.371     7.22 \[7.17;7.37\]
                     L-NMMA^\*^   7.48 \[7.44,7.49\]    7.32 \[7.31 ;7.341   7.29 \[7.26;7.321     7.24 \[7.16;7.30\]
  Hepatic            ETX^\*^      24 \[15;32\]          26 \[18;30\]         34 \[28;51\]          61 \[31;123\]
  venous Lac/Pyr     NOR^\*^      31 \[21;37\]          38 \[25;66\]         95 \[49;1 01\]        104 \[41 ;204\]
  ratio              L-NMMA^\*^   21 \[18;29\]          28 \[28;50\]         60 \[40;95\]          148 \[67;187\]
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